This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raptor Pharmaceutical Corp. Reports First Quarter Fiscal Year 2013 Financial Results

On December 21, 2012, the Company received a notice from the FDA in which the FDA required additional time to complete its review of Raptor's NDA for RP103 for the potential treatment of nephropathic cystinosis and extended the initial PDUFA goal date from January 30, 2013 to April 30, 2013.

In December 2012, Raptor changed its year end from August 31 to December 31. Therefore the Company will file a transitional Annual Report, on or before March 18, 2013, on Form 10-KT for the short period from September 1, 2012 to December 31, 2012. Thereafter, the Company will file quarterly reports on Form 10-Q for each calendar quarter.

About Raptor Pharmaceutical Corp.

Raptor seeks to research, develop, and provide access to medicines that improve life for patients with severe and rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis, Huntington's Disease, and aldehyde dehydrogenase deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.

For additional information, please visit .

The Raptor Pharmaceutical Corp. logo is available at


This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Raptor will be able to launch RP103 for the potential treatment of nephropathic cystinosis; that Raptor will be able to draw on the second $25 million tranche under the loan agreement with HealthCare Royalty Partners; and that Raptor will receive regulatory approval from the FDA of RP103 for the potential treatment of nephropathic cystinosis by April 30, 2013, or at all. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include: that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including: Raptor's annual report on Form 10-K, filed with the SEC on November 14, 2012, and Raptor's quarterly report on Form 10-Q filed with the SEC on January 9, 2013, all which are available free of charge on the SEC's web site at . Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.
Raptor Pharmaceutical Corp.
(A Development Stage Company)
Condensed Consolidated Balance Sheets
(In thousands, except per share data, or unless otherwise specified)
  November 30, August 31,
  2012 2012
  (unaudited) (1)
Current assets:    
Cash and cash equivalents  $ 13,426  $ 23,580
Restricted cash  163  169
Short-term investments  22,056  15,307
Prepaid expenses and other  2,688  3,111
Total current assets  38,333  42,167
Intangible assets, net  2,168  2,205
Goodwill  3,275  3,275
Fixed assets, net  397  403
Deposits  26  105
Deferred offering costs  116  134
Debt issuance costs  161  -- 
Total assets  $ 44,476  $ 48,289
Current liabilities:    
Accounts payable  $ 1,846  $ 1,601
Accrued liabilities  2,972  2,652
Common stock warrant liability  16,238  17,266
Deferred rent  8  14
Capital lease liability - current  8  8
Total current liabilities  21,072  21,541
Capital lease liability - long-term  11  13
Total liabilities  21,083  21,554
Commitments and contingencies    
Stockholders' equity:    
Preferred stock, $0.001 par value per share, 15,000 shares authorized, zero shares issued and outstanding -- --
Common stock, $0.001 par value per share, 150,000 shares authorized 52,098 and 50,568 shares issued and outstanding as at November 30, 2012 and August 31, 2012, respectively  52  51
Additional paid-in capital  153,454  143,380
Accumulated other comprehensive loss  (68)  (50)
Deficit accumulated during development stage  (130,045)  (116,646)
Total stockholders' equity  23,393  26,735
Total liabilities and stockholders' equity  $ 44,476  $ 48,289
(1) Derived from the Company's audited consolidated financial statements as of August 31, 2012.
Raptor Pharmaceutical Corp.
(A Development Stage Company)
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share data, or unless otherwise specified)
      For the period
      September 8,
  For the three months ended 2005
  November 30 (inception) to
      November 30,
  2012 2011 2012
Revenues:  $ --  $ --  $ --
Operating expenses:      
General and administrative  6,365  2,336  37,941
Research and development  6,785  5,016  67,466
Total operating expenses  13,150  7,352  105,407
Loss from operations  (13,150)  (7,352)  (105,407)
Interest income  119  64  832
Interest expense      0  (1)  (119)
Foreign currency transaction gain  60  59  234
Realized gain on short-term investments      0      0  214
Unrealized loss on short-term investments  (64)  (35)  (66)
Adjustment to fair value of common stock warrants  (364)  (4,168)  (25,733)
Net loss  (13,399)  (11,433)  (130,045)
Other comprehensive loss      
Foreign currency translation adjustment  (18)  (8)  (68)
Comprehensive loss  $ (13,417)  $ (11,441)  $ (130,113)
Net loss per share:      
Basic and diluted  $ (0.26)  $ (0.25)  
Weighted-average shares outstanding used to compute:      
Basic and diluted  51,557  45,623  
CONTACT: Georgia Erbez
         Chief Financial Officer
         Raptor Pharmaceutical Corp.
         (415) 382-1111 x204

company logo

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs